Company BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
152.2 USD +1.11% Intraday chart for BeiGene, Ltd. +3.49% -15.63%

Business Summary

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Number of employees: 10,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
1,416 100.0 % 2,459 100.0 % +73.65%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
45.9 %
503 35.5 % 1,128 45.9 % +124.46%
China
44.8 %
840 59.3 % 1,102 44.8 % +31.18%
Europe
8.2 %
-- 202 8.2 % -
Rest of World
1.1 %
73 5.2 % 27 1.1 % -63.70%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,244,457,968 1,222,239,074 ( 98.21 %) 0 98.21 %

Shareholders

NameEquities%Valuation
AMGEN INC.
19.55 %
246,269,426 19.55 % 2 719 M $
Capital Research & Management Co. (International Investors)
8.210 %
103,421,157 8.210 % 1 142 M $
John Oyler
6.073 %
76,503,298 6.073 % 845 M $
HHLR Advisors Ltd.
6.000 %
75,588,463 6.000 % 835 M $
20,812,777 1.652 % 230 M $
Capital International, Inc.
0.6650 %
8,376,845 0.6650 % 92 M $
GF Fund Management Co., Ltd.
0.6058 %
7,632,000 0.6058 % 84 M $
China Asset Management Co., Ltd.
0.2822 %
3,555,000 0.2822 % 39 M $
2,718,464 0.2158 % 30 M $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
0.2120 %
2,670,100 0.2120 % 29 M $
NameEquities%Valuation
Penghua Fund Management Co., Ltd.
6.337 %
7,290,681 6.337 % 116 M $
Wanjia Asset Management Co., Ltd.
4.489 %
5,165,018 4.489 % 82 M $
ICBC Credit Suisse Asset Management Co., Ltd.
4.041 %
4,648,832 4.041 % 74 M $
Bank of China Investment Management Co., Ltd.
2.640 %
3,037,160 2.640 % 48 M $
Bosera Asset Management Co., Ltd.
2.328 %
2,678,498 2.328 % 43 M $
Abu Dhabi Investment Authority (Investment Management)
2.092 %
2,407,263 2.092 % 38 M $
Taiping Life Insurance Co. Ltd. (Investment Portfolio)
2.092 %
2,407,263 2.092 % 38 M $
China International Capital Corp. Ltd. (Invt Management)
1.799 %
2,069,546 1.799 % 33 M $
GF Fund Management Co., Ltd.
1.585 %
1,823,581 1.585 % 29 M $
Guangxi Tongfu Kexing Investment Management LP
1.255 %
1,444,358 1.255 % 23 M $
NameEquities%Valuation
Baker Bros. Advisors LP
10.91 %
10,568,897 10.91 % 1 508 M $
Capital Research & Management Co. (International Investors)
7.290 %
7,064,428 7.290 % 1 008 M $
HHLR Advisors Ltd. (Cayman Islands)
5.342 %
5,176,906 5.342 % 739 M $
PRIMECAP Management Co.
5.162 %
5,001,839 5.162 % 714 M $
Baillie Gifford & Co.
3.848 %
3,728,730 3.848 % 532 M $
Temasek Holdings Pte Ltd.
3.110 %
3,014,171 3.110 % 430 M $
T. Rowe Price International Ltd.
2.091 %
2,026,094 2.091 % 289 M $
Fidelity Management & Research Co. LLC
1.734 %
1,680,463 1.734 % 240 M $
BlackRock Advisors LLC
0.9349 %
905,962 0.9349 % 129 M $
Capital International, Inc.
0.8858 %
858,364 0.8858 % 122 M $

Company contact information

BeiGene Ltd.

94 Solaris Avenue Camana Bay

KY1-1108, George Town

+345-949-4123

http://www.beigene.com
address BeiGene, Ltd.(BGNE)